Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response

Show simple item record

dc.contributor.author SUCCESS Study Investigators
dc.contributor.author Färkkilä, Martti
dc.date.accessioned 2018-10-22T11:07:01Z
dc.date.available 2018-10-22T11:07:01Z
dc.date.issued 2010-10
dc.identifier.citation SUCCESS Study Investigators & Färkkilä , M 2010 , ' Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response ' , Hepatology , vol. 52 , no. 4 , pp. 1201-1207 . https://doi.org/10.1002/hep.23816
dc.identifier.other PURE: 117221038
dc.identifier.other PURE UUID: 6e9a7129-c693-4eca-bb81-a8a4ee745ecd
dc.identifier.other WOS: 000282613000005
dc.identifier.other Scopus: 77957952655
dc.identifier.other ORCID: /0000-0002-0250-8559/work/49701776
dc.identifier.uri http://hdl.handle.net/10138/252447
dc.description.abstract The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RI3V) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-nave patients from 133 centers were treated with PEG-IFN alfa-26 (1.5 mu g/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatii is C virus (HCV) RNA and a >= 2-logio drop in IICV RNA levels at week 12 (slow responders) were randomized 1:1 to receive 48 weeks (n = 86) or 72 weeks (n = 73) of treatment. Sustained virologic response (SVR) rates were 43% in slow responders treated for 48 weeks and 48% in slow responders treated for 72 weeks (P = 0.644). Relapse rates were similar in slow responders treated for 48 or 72 weeks (47% versus 33%, P = 0.169). The safety profile was similar in both treatment arms; serious adverse events leading to discontinuation of treatment were observed in 3.5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a en
dc.format.extent 7
dc.language.iso eng
dc.relation.ispartof Hepatology
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject PLUS RIBAVIRIN
dc.subject TREATMENT DURATION
dc.subject COMBINATION THERAPY
dc.subject INFECTION
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response en
dc.type Article
dc.contributor.organization Department of Medicine
dc.contributor.organization Clinicum
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1002/hep.23816
dc.relation.issn 0270-9139
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Buti_et_al_2010_Hepatology.pdf 196.8Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record